326 related articles for article (PubMed ID: 19265678)
1. Amyloid beta peptides with an additional cysteine residue can enhance immunogenicity and reduce the amyloid beta burden in an Alzheimer's disease mouse model.
Matsuda J; Kaminaka K; Nozaki C
Biochem Biophys Res Commun; 2009 Apr; 382(1):149-52. PubMed ID: 19265678
[TBL] [Abstract][Full Text] [Related]
2. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response.
Zou J; Yao Z; Zhang G; Wang H; Xu J; Yew DT; Forster EL
J Neurol Sci; 2008 Sep; 272(1-2):87-98. PubMed ID: 18571202
[TBL] [Abstract][Full Text] [Related]
3. Reduction of amyloid beta-peptide accumulation in Tg2576 transgenic mice by oral vaccination.
Ishii-Katsuno R; Nakajima A; Katsuno T; Nojima J; Futai E; Sasagawa N; Yoshida T; Watanabe Y; Ishiura S
Biochem Biophys Res Commun; 2010 Sep; 399(4):593-9. PubMed ID: 20682291
[TBL] [Abstract][Full Text] [Related]
4. Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease.
Nemirovsky A; Fisher Y; Baron R; Cohen IR; Monsonego A
Vaccine; 2011 May; 29(23):4043-50. PubMed ID: 21473952
[TBL] [Abstract][Full Text] [Related]
5. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease.
Wang CY; Finstad CL; Walfield AM; Sia C; Sokoll KK; Chang TY; Fang XD; Hung CH; Hutter-Paier B; Windisch M
Vaccine; 2007 Apr; 25(16):3041-52. PubMed ID: 17287052
[TBL] [Abstract][Full Text] [Related]
6. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses.
Chackerian B; Rangel M; Hunter Z; Peabody DS
Vaccine; 2006 Sep; 24(37-39):6321-31. PubMed ID: 16806604
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Alzheimer's disease.
McGeer PL; McGeer E
Sci Aging Knowledge Environ; 2004 Jul; 2004(27):pe29. PubMed ID: 15243154
[TBL] [Abstract][Full Text] [Related]
8. [Novel vaccine therapy for Alzheimer's disease--recent progress and our approach].
Okura Y; Matsumoto Y
Brain Nerve; 2008 Aug; 60(8):931-40. PubMed ID: 18717197
[TBL] [Abstract][Full Text] [Related]
9. HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele.
Zota V; Nemirovsky A; Baron R; Fisher Y; Selkoe DJ; Altmann DM; Weiner HL; Monsonego A
J Immunol; 2009 Sep; 183(5):3522-30. PubMed ID: 19675171
[TBL] [Abstract][Full Text] [Related]
10. Immunogenic, antigenic, fibrillogenic and inflammatory properties of new simplified beta-amyloid peptides.
Rossi M; Piovesan P; Ghirardi O; Mastroianni D; Bombardi V; Battistini L; Cencioni MT; Capobianco D; Borsini F; Colombo M; Verdoliva A
Mol Immunol; 2009 Aug; 46(13):2524-32. PubMed ID: 19535144
[TBL] [Abstract][Full Text] [Related]
11. Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging.
Jensen MT; Mottin MD; Cracchiolo JR; Leighty RE; Arendash GW
Neuroscience; 2005; 130(3):667-84. PubMed ID: 15590151
[TBL] [Abstract][Full Text] [Related]
12. Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein and GM-CSF reduces amyloid load in the brain.
Kim HD; Kong FK; Cao Y; Lewis TL; Kim H; Tang DC; Fukuchi K
Neurosci Lett; 2004 Nov; 370(2-3):218-23. PubMed ID: 15488326
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
Geylis V; Steinitz M
Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
[TBL] [Abstract][Full Text] [Related]
14. [Abeta vaccine therapy for Alzheimer's disease].
Hara H
Rinsho Shinkeigaku; 2005 Nov; 45(11):867-9. PubMed ID: 16447748
[TBL] [Abstract][Full Text] [Related]
15. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.
Oddo S; Billings L; Kesslak JP; Cribbs DH; LaFerla FM
Neuron; 2004 Aug; 43(3):321-32. PubMed ID: 15294141
[TBL] [Abstract][Full Text] [Related]
16. Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease.
Kim HD; Maxwell JA; Kong FK; Tang DC; Fukuchi K
Biochem Biophys Res Commun; 2005 Oct; 336(1):84-92. PubMed ID: 16126169
[TBL] [Abstract][Full Text] [Related]
17. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety.
Okura Y; Miyakoshi A; Kohyama K; Park IK; Staufenbiel M; Matsumoto Y
Proc Natl Acad Sci U S A; 2006 Jun; 103(25):9619-24. PubMed ID: 16769900
[TBL] [Abstract][Full Text] [Related]
18. Design and development of non-fibrillar amyloid beta as a potential Alzheimer vaccine.
Subramanian S; Bandopadhyay D; Mishra PK; Mathew M; John M
Biochem Biophys Res Commun; 2010 Apr; 394(2):393-7. PubMed ID: 20214884
[TBL] [Abstract][Full Text] [Related]
19. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.
Yu YZ; Wang WB; Chen A; Chang Q; Liu S; Zhao M; Wang S; Qiu WY; Pang XB; Xu Q; Sun ZW
J Alzheimers Dis; 2014; 41(1):243-60. PubMed ID: 24625800
[TBL] [Abstract][Full Text] [Related]
20. Clearing tau pathology with Abeta immunotherapy--reversible and irreversible stages revealed.
Hutton M; McGowan E
Neuron; 2004 Aug; 43(3):293-4. PubMed ID: 15294135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
